glp 1 and atrial fibrillation Glucagon-like peptide-1 incidence: Associations independent of weight loss GLP-1 receptor agonists confer better

Woodard JS, Abrams GA

Gastrointestinal Side Effects The most common adverse events were gastrointestinal in nature, as expected for this drug class: Nausea the most frequently reported GI side effect, typically most pronounced during dose escalation and diminishing over time Diarrhea reported at moderate frequency Constipation less common than nausea but clinically relevant for some participants Vomiting generally mild and often transient These GI effects are mechanistically linked to GLP-1 receptor activation (slowed gastric emptying, central appetite suppression) and are a recognized feature of all GLP-1-based therapies

Shifting from the single to the multitarget paradigm in drug discovery

[115] has shown a direct relationship between atherosclerosis and increased levels of TMAO

This pattern likely reflects differences in baseline fitness: individuals who regularly perform longer workouts are generally more fit and therefore exhibit lower resting heart rate and higher HRV[2]